Coronavirus Drugs Already in the Pipeline

It's not just chloroquine. Other existing medicines are being brought to bear against COVID-19. We look at what drugs have promise against COVID-19, and when they will get here.

What drugs will be available to treat COVID-19? Here's a quick rundown and a timeline for when to expect them. Note that these drugs have not been proven yet in trials of patients suffering from the novel coronavirus, and as such do not have official FDA approval, but they may still be helpful.

A lot of attention has been paid to existing antimalarials (in the chloroquine family) or flu drugs (favipiravir)

The antimalarials are in short supply, but production is ramping up. Mylan (MYL) and Teva Pharmaceuticals (TEVA) plan to jump-start production of hydroxychloroquine, which is also approved for treating lupus or rheumatoid arthritis. Teva says it will donate 6 million doses of hydroxychloroquine sulfate tablets tablets through wholesalers to hospitals by March 31. We expect them to be widely available in mid-April.

Subscribe to Kiplinger’s Personal Finance

Be a smarter, better informed investor.

Save up to 74%

Sign up for Kiplinger’s Free E-Newsletters

Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.

Profit and prosper with the best of expert advice - straight to your e-mail.

Sign up

Remdesivir has been studied for years as an experimental antiviral, most recently for its potential against Ebola. Doctors were throwing it against COVID-19 in a "try something" approach, to the point that demand led its manufacturer, Gilead (GILD), to limit its used to clinical trials. Six large studies are ongoing. The first should report results on April 3, the second in mid-April, and two more in May.

One side effect of COVID-19 is a so-called "cytokine storm," in which the virus causes the immune system to overreact. Actemra by Roche (RHHBY) and Kevzara, by Sanofi (SNY) and Regeneron (REGN), are existing arthritis drugs which may also be able to counter a cytokine storm. Currently available, but starting testing for COVID-19 use.

Convalescent plasma, blood plasma from patients who have recovered from the virus, with their antibodies in it. Still in research, availability at least nine months away.

Artificial antibodies, which are similar to blood plasma but more consistent. Trials should begin in early summer, availability possible in the early fall. Companies working on this idea: Regeneron, Eli Lilly (LLY) with AbCellera, Vir Biotechnology (VIR), and Biogen (BIIB).

David Payne
Staff Economist, The Kiplinger Letter

David is both staff economist and reporter for The Kiplinger Letter, overseeing Kiplinger forecasts for the U.S. and world economies. Previously, he was senior principal economist in the Center for Forecasting and Modeling at IHS/GlobalInsight, and an economist in the Chief Economist's Office of the U.S. Department of Commerce. David has co-written weekly reports on economic conditions since 1992, and has forecasted GDP and its components since 1995, beating the Blue Chip Indicators forecasts two-thirds of the time. David is a Certified Business Economist as recognized by the National Association for Business Economics. He has two master's degrees and is ABD in economics from the University of North Carolina at Chapel Hill.